Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 13/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29890916 | 1.00 | FURIN (0.47) | FURINGPR119CKS1BSKP1SKP2 | |
| SCHEMBL29891252 | 0.92 | FURIN (0.48) | FURINGPR119CKS1BSKP1SKP2 | |
| SCHEMBL21550925 | 0.92 | FURIN (0.48) | FURINGPR119CKS1BSKP1SKP2 | |
| SCHEMBL21551462 | 0.92 | FURIN (0.50) | FURIN | |
| SCHEMBL26077334 | 0.89 | FURIN (0.49) | FURIN | |
| SCHEMBL21553798 | 0.88 | FURIN (0.49) | FURIN | |
| SCHEMBL29890997 | 0.88 | FURIN (0.49) | FURIN | |
| SCHEMBL21551400 | 0.86 | FURIN (0.61) | FURIN | |
| SCHEMBL27032801 | 0.86 | FURIN (0.48) | FURIN | |
| SCHEMBL21564422 | 0.84 | FURIN (0.54) | FURINGPR119CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | FURIN 1/4885GPR119 2318/4885CKS1B 713/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | FURIN 1/4885GPR119 2318/4885CKS1B 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.